TissGeneSummary for ANKRD30BL |
Gene summary |
Basic gene information | Gene symbol | ANKRD30BL |
Gene name | ||
Synonyms | ||
Cytomap | UCSC genome browser: | |
Type of gene | ||
RefGenes | ||
Description | ||
Modification date | ||
dbXrefs | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ANKRD30BL | |
BioGPS: 100132004 | ||
Pathway | NCI Pathway Interaction Database: ANKRD30BL | |
KEGG: ANKRD30BL | ||
REACTOME: ANKRD30BL | ||
Pathway Commons: ANKRD30BL | ||
Context | iHOP: ANKRD30BL | |
ligand binding site mutation search in PubMed: ANKRD30BL | ||
UCL Cancer Institute: ANKRD30BL | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | ||
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of ANKRD30BL | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for ANKRD30BL |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
Top |
TissGene-miRNA for ANKRD30BL |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for ANKRD30BL |
TissGeneSNV for ANKRD30BL |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.A70G | SARC | 2 |
p.T247M | BLCA | 1 |
p.E118K | HNSC | 1 |
p.T247M | CESC | 1 |
p.A70G | LIHC | 1 |
p.E165A | ESCA | 1 |
p.R180K | PRAD | 1 |
p.T247M | PCPG | 1 |
p.S230C | LUAD | 1 |
p.K193Q | SARC | 1 |
p.S230C | HNSC | 1 |
p.T74I | ESCA | 1 |
p.E242* | KIRC | 1 |
p.A70G | CHOL | 1 |
p.D257N | SKCM | 1 |
p.E104K | MESO | 1 |
p.D201N | SKCM | 1 |
p.E231Q | HNSC | 1 |
p.A119D | LUAD | 1 |
p.S230C | SKCM | 1 |
p.G232E | SKCM | 1 |
p.A7T | CESC | 1 |
p.T247M | LUAD | 1 |
p.D163N | LUAD | 1 |
p.D38Y | ACC | 1 |
p.A70G | ESCA | 1 |
p.S230C | PRAD | 1 |
p.R243G | KIRC | 1 |
p.E242K | SKCM | 1 |
p.G171D | ESCA | 1 |
p.A199S | HNSC | 1 |
p.A248S | BLCA | 1 |
p.S230C | THCA | 1 |
p.S230C | BLCA | 1 |
p.L113V | PAAD | 1 |
p.V142F | MESO | 1 |
p.A70G | ACC | 1 |
p.A178V | PAAD | 1 |
p.S230C | PAAD | 1 |
p.S159F | BLCA | 1 |
p.E149D | UCEC | 1 |
p.R254K | SKCM | 1 |
p.G228E | SKCM | 1 |
p.S230C | KIRC | 1 |
Top |
TissGeneCNV for ANKRD30BL |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for ANKRD30BL |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Chimerdb3.0 | TopHat-Fusion | STAD | TCGA-L5-A4OR-01A4 | ANKRD30BL-PDE3A | 5'UTR-5'UTR | chr2:133012127 | chr12:20704404 |
Chimerdb3.0 | TopHat-Fusion | LAML | TCGA-AB-3007-03A | ANKRD30BL-MPO | 5'UTR-CDS | chr2:133012123 | chr17:56350992 |
Chimerdb3.0 | TopHat-Fusion | LAML | TCGA-AB-3007-03A | ANKRD30BL-MPO | 5'UTR-CDS | chr2:133012591 | chr17:56356985 |
Chimerdb3.0 | TopHat-Fusion | LAML | TCGA-AB-3007-03A | ANKRD30BL-MPO | 5'UTR-CDS | chr2:133012592 | chr17:56349213 |
Chimerdb3.0 | TopHat-Fusion | LAML | TCGA-AB-3007-03A | ANKRD30BL-MPO | 5'UTR-CDS | chr2:133012753 | chr17:56355478 |
Chimerdb3.0 | TopHat-Fusion | LAML | TCGA-AB-2937-03A | ANKRD30BL-PDE3A | 5'UTR-5'UTR | chr2:133012085 | chr12:20704435 |
Chimerdb3.0 | TopHat-Fusion | LAML | TCGA-AB-2937-03A | ANKRD30BL-PDE3A | 5'UTR-5'UTR | chr2:133012481 | chr12:20704440 |
Chimerdb3.0 | TopHat-Fusion | LAML | TCGA-AB-2984-03A | ANKRD30BL-PDE3A | 5'UTR-5'UTR | chr2:133012512 | chr12:20704430 |
Chimerdb3.0 | TopHat-Fusion | LAML | TCGA-AB-2984-03A | ANKRD30BL-PDE3A | 5'UTR-5'UTR | chr2:133012563 | chr12:20704432 |
Chimerdb3.0 | TopHat-Fusion | LAML | TCGA-AB-2984-03A | ANKRD30BL-PDE3A | 5'UTR-5'UTR | chr2:133012574 | chr12:20704447 |
Chimerdb3.0 | TopHat-Fusion | LAML | TCGA-AB-2987-03A | ANKRD30BL-PDE3A | 5'UTR-5'UTR | chr2:133012599 | chr12:20704492 |
Chimerdb3.0 | TopHat-Fusion | BRCA | TCGA-AC-A3OD-01B | ANKRD30BL-PDE3A | 5'UTR-5'UTR | chr2:133012678 | chr12:20704409 |
Top |
TissGeneNet for ANKRD30BL |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for ANKRD30BL |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for ANKRD30BL |
TissGeneDrug for ANKRD30BL |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for ANKRD30BL |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |